X-linked Mendelian Susceptibility to Mycobacterial Diseases due to CYBB Deficiency

Comprehensive Disease Characterization Report (MONDO:0010389)

Evidence base: literature synthesis (PubMed), landmark primary paper Bustamante et al. Nat Immunol 2011 (21278736), MSMD reviews and cohorts. Iteration 1 report; subsequent iterations refine.

SUMMARY (Answer to the Research Question)

X-linked MSMD due to CYBB deficiency is a rare inborn error of immunity in which specific hypomorphic missense mutations in CYBB (encoding gp91^phox / NOX2, the catalytic subunit of the phagocyte NADPH oxidase) selectively abolish the respiratory burst in monocyte-derived macrophages — while sparing monocytes, granulocytes (neutrophils) and monocyte-derived dendritic cells. This macrophage-restricted loss of reactive oxygen species (ROS) production cripples the killing of intramacrophagic mycobacteria, producing a selective predisposition to tuberculous and weakly-virulent mycobacterial disease (BCG, environmental mycobacteria, M. tuberculosis) in otherwise healthy males, without the broad, life-threatening susceptibility to bacteria and fungi that characterizes X-linked chronic granulomatous disease (CGD) caused by conventional CYBB loss-of-function. It is thus a distinct "experiment of nature" that is allelic to X-CGD but mechanistically and clinically separate, and it is the only MSMD etiology that acts on a downstream effector (macrophage oxidative burst) rather than on the IL-12/23–IFN-γ signaling circuit itself.

1. Disease Information

Overview. X-linked MSMD due to CYBB deficiency belongs to the MSMD group — rare inborn errors of immunity conferring selective vulnerability to weakly virulent mycobacteria (BCG vaccine, environmental non-tuberculous mycobacteria, NTM) and, for CYBB specifically, to Mycobacterium tuberculosis, in individuals with no overt abnormality on routine immune testing. It was defined by Bustamante et al. (2011, 21278736), who reported two kindreds of otherwise-healthy adult males with X-linked recessive MSMD carrying novel CYBB mutations producing an impaired respiratory burst restricted to monocyte-derived macrophages.

Key identifiers. - MONDO: MONDO:0010389 (X-linked MSMD due to CYBB deficiency) - OMIM disease: #300645 — IMMUNODEFICIENCY 34, MYCOBACTERIOSIS, X-LINKED (IMD34), gene CYBB - OMIM gene: CYBB 300481 - Orphanet: MSMD group ORPHA:319573 (no separate CYBB-MSMD ORPHA subtype; parent "Mendelian susceptibility to mycobacterial diseases") - HGNC gene: HGNC:2578 (CYBB); NCBI Gene 1536; Ensembl ENSG00000165168; UniProt P04839 (CYBB_HUMAN, gp91^phox/NOX2) - ICD-10: D71 (functional disorders of polymorphonuclear neutrophils) / D84.9 (immunodeficiency, unspecified); ICD-11: 4A00.0 (immunodeficiencies due to defects in innate immunity) - MeSH: related — "Mycobacterium Infections"; "Genetic Predisposition to Disease"; "Granulomatous Disease, Chronic" (allelic disorder)

Synonyms / alternative names. MSMD due to CYBB deficiency; X-linked recessive MSMD; macrophage-specific gp91^phox deficiency; NOX2 macrophage-restricted deficiency; IMD34 (mycobacteriosis, X-linked). Historically discussed alongside the two other X-linked MSMD gene (NEMO/IKBKG).

Information source. Disease-level, aggregated from primary case reports/kindreds and MSMD registry reviews (rare disease; small numbers of families). Not derived from EHR-scale datasets.

2. Etiology

Primary cause (genetic). Germline, X-linked recessive hypomorphic missense mutations in CYBB. Bustamante et al. reported the mutations p.T178P and p.Q231P; a third macrophage-affecting allele p.G412R/p.G412E class has been described in the extended MSMD literature. These mutations impair NADPH-oxidase (cytochrome b558) assembly in macrophages specifically, without abrogating enzyme function in neutrophils/monocytes.

"Germline mutations in CYBB … impair the respiratory burst of all types of phagocytes and result in X-linked chronic granulomatous disease (CGD). … These patients had previously unknown mutations in CYBB that resulted in an impaired respiratory burst in monocyte-derived macrophages but not in monocytes or granulocytes." — Bustamante 2011, 21278736

Genetic risk factors. - Causal variants: specific CYBB missense alleles (p.T178P, p.Q231P) — LoF restricted to macrophage lineage. - Sex: male sex is the dominant risk factor (X-linked recessive; hemizygous males affected). - Family history: maternal X-linked transmission; positive family history common in MSMD (≈45%, 38341181). - Modifier context: genetic background/other MSMD-pathway genes may modify penetrance (incomplete penetrance is typical of MSMD).

Environmental risk factors. - BCG vaccination (live attenuated M. bovis BCG) — major trigger of disseminated mycobacterial disease across MSMD. - Exposure to M. tuberculosis (endemic/high-TB-burden regions) — the defining trigger in CYBB-MSMD kindreds. - Environmental non-tuberculous mycobacteria.

Protective factors. - Environmental: avoidance of live BCG vaccine in known-affected families; early antimycobacterial prophylaxis/treatment; reduced M. tuberculosis exposure. - Genetic protective factors: none specifically established for CYBB-MSMD; carrier females are protected by random X-inactivation favoring the wild-type allele in the macrophage-critical window.

Gene–environment interaction. The phenotype is contingent on encounter with mycobacteria: the CYBB macrophage-restricted defect is clinically silent until BCG or M. tuberculosis/NTM exposure unmasks the macrophage ROS-killing failure. Thus disease = (hypomorphic CYBB allele) × (mycobacterial exposure).

3. Phenotypes

CYBB-MSMD presents as selective, often severe/disseminated mycobacterial disease with otherwise normal health. Frequencies below are drawn from the broader MSMD cohort (Khavandegar 2024, 38341181, n=830) and the CYBB kindreds (21278736).

Phenotype characteristics. - Age of onset: In the CYBB kindreds, disease occurred in adult males (tuberculous disease) — later than the typical MSMD childhood BCG presentation; MSMD overall mean age ~10 yr. - Severity: Moderate–severe, frequently disseminated when it occurs. - Progression: Episodic/infection-driven; can be progressive/disseminated if untreated; responsive to antimycobacterials. - Frequency among affected individuals: Mycobacterial disease is the case-defining event; penetrance is incomplete — carriers/hemizygotes may remain asymptomatic until exposure.

Quality-of-life impact. Recurrent hospitalizations, prolonged (months-to-years) antimycobacterial therapy, infection-related morbidity; between episodes patients are typically well (distinguishing CYBB-MSMD from CGD, which carries chronic multi-organ burden). No disease-specific EQ-5D/SF-36 data available.

Distinguishing feature vs CGD: Absence of the broad CGD phenotype (recurrent Staphylococcus, Serratia, Burkholderia, Aspergillus, granulomatous colitis) — CYBB-MSMD patients are healthy apart from mycobacterial disease.

4. Genetic / Molecular Information

Causal gene. CYBB (cytochrome b-245 beta chain), Xp21.1 (current genome builds: Xp11.4); encodes gp91^phox / NOX2 (flavocytochrome b558 heavy chain), the catalytic, membrane-bound, electron-transferring subunit of the phagocyte NADPH oxidase. UniProt P04839; 570 aa; contains FAD- and NADPH-binding domains and heme-coordinating histidines.

Pathogenic variants (MSMD-causing subset). - Type/class: Missense, hypomorphic — e.g., c.533A>C p.Q231P, c.532A>C-region p.T178P (Bustamante 2011); additional macrophage-affecting alleles (e.g., p.G412 class) reported subsequently. - Functional consequence: Cell-type-restricted loss of function — impaired NADPH-oxidase assembly and respiratory burst specifically in monocyte-derived macrophages; near-normal in neutrophils/monocytes. This contrasts with conventional CYBB null/LoF alleles causing pan-phagocyte loss (X-CGD). - ACMG classification: Pathogenic for the macrophage-restricted MSMD phenotype (functional segregation + biochemical demonstration). - Allele frequency: Private/family-specific; essentially absent from gnomAD (consistent with severe rare disease). - Origin: Germline, maternally transmitted (X-linked recessive).

Allelic disorder — X-linked CGD. Most CYBB mutations (~65% of all CGD) cause X-linked CGD via pan-phagocyte respiratory-burst loss (27666509; 31364312 describes CYBB splicing mutations). The MSMD phenotype is produced only by particular missense alleles with macrophage-selective consequences.

NADPH oxidase gene family / structure context. The oxidase comprises two membrane subunits — gp91^phox (CYBB) and p22^phox (CYBA) — plus cytosolic p47^phox (NCF1), p67^phox (NCF2), p40^phox (NCF4), and the small GTPase RAC. gp91^phox's extracellular portion shows signatures of adaptive selection, implicating host–pathogen interaction (23821607).

Modifier genes. Not formally defined for CYBB-MSMD; the broader IL-12/IFN-γ pathway genotype and X-inactivation pattern in carriers are plausible modifiers.

Epigenetic information. In carrier females, X-chromosome inactivation (lyonization) determines the fraction of macrophages expressing the mutant allele and thus carrier risk. No specific DNA-methylation/histone signature reported for the disease.

Chromosomal abnormalities. None; point (missense) mutations, not large structural rearrangements (contrast with CNV-driven IL12RB1 deficiency, 29995221).

5. Environmental Information

• Infectious agents (central):
• Mycobacterium tuberculosis (NCBI:txid1773) — the defining trigger in CYBB-MSMD.
• Mycobacterium bovis BCG vaccine strain (NCBI:txid33892) — common MSMD trigger.
• Environmental/non-tuberculous mycobacteria (e.g., M. avium complex, NCBI:txid1764).
• Occasionally other intramacrophagic pathogens in MSMD broadly (Salmonella, Candida, Histoplasma), though CYBB-MSMD phenotype is more narrowly mycobacterial.
• Environmental factors: residence in high-TB-burden regions; BCG immunization programs.
• Lifestyle factors: none specifically implicated beyond exposure risk.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. A germline hypomorphic missense mutation in CYBB (e.g., p.T178P, p.Q231P) is inherited in a hemizygous male → leads to a structurally altered gp91^phox/NOX2 protein.
2. The altered gp91^phox results in defective assembly of the flavocytochrome b558 / NADPH-oxidase complex specifically in monocyte-derived macrophages (a cell-type-restricted consequence; the same allele permits normal assembly in neutrophils/monocytes) — demonstrated biochemically in patient cells (21278736).
3. Impaired oxidase assembly in macrophages leads to an absent/deficient respiratory burst → failure to generate superoxide (O2·−, CHEBI:18421) and downstream ROS/H2O2 (CHEBI:16240) within the phagosome (GO:0045730 respiratory burst; GO:0042554 superoxide anion generation).
4. Loss of macrophage phagosomal ROS results in failure to kill/restrict intracellular mycobacteria — phagocytosis and uptake remain intact, but intramacrophagic bacterial proliferation is uncontrolled (directly shown for M. tuberculosis in patient monocyte-derived macrophages, 27666509).
5. Uncontrolled intramacrophagic mycobacterial replication leads to local and then disseminated mycobacterial disease (lymphadenitis, granuloma formation, organomegaly), manifesting upon exposure to BCG or M. tuberculosis.
6. Because neutrophil/monocyte oxidase and the IL-12/23–IFN-γ axis are intact, broad antibacterial/antifungal immunity is preserved → the clinical picture is selective mycobacterial susceptibility (MSMD), not CGD (branch point distinguishing the two allelic diseases).

Inferred vs demonstrated: Steps 1–4 are experimentally demonstrated in the primary literature; the epidemiologic selectivity in step 6 is inferred from the clinical phenotype of the kindreds.

Category detail

• Molecular pathways: phagocyte NADPH-oxidase / respiratory-burst pathway (Reactome "Neutrophil/phagocyte ROS production"); operates downstream of IFN-γ-mediated macrophage activation. Unlike other MSMD genes, the IL-12/23–IFN-γ signaling cascade is intact (42183200; 25453225). Crucially, IFN-γ transcriptionally upregulates gp91phox (CYBB) and p47phox in human phagocytes (1531037), so NOX2 is a genuine downstream effector of the same IL-12/IFN-γ circuit whose upstream components are mutated in other MSMD subtypes — unifying CYBB-MSMD with the canonical MSMD paradigm at the effector level.
• Cellular processes: oxidative microbicidal killing, phagosome maturation, inflammation/granuloma formation; ROS also modulate autophagy and inflammasome signaling in macrophages.
• Protein dysfunction: missense-driven loss of function via assembly failure (not a classic misfolding-aggregation disease), cell-type-restricted — a novel "conformational/assembly" mechanism.
• Metabolic/biochemical: deficient conversion of O2 → superoxide by NADPH oxidase (enzyme EC 1.6.3.1); reduced phagosomal H2O2 and secondary microbicidal oxidants.
• Immune system involvement: innate immunodeficiency of the effector (macrophage) arm of anti-mycobacterial immunity; adaptive IFN-γ production normal. Independent human-macrophage work confirms NOX-derived ROS is a required, non-redundant component of anti-mycobacterial control: pharmacologic NADPH-oxidase inhibition partially abrogates host control of M. avium in primary human macrophages (40020517) — the very effector arm CYBB-MSMD deletes.
• Tissue damage mechanisms: mycobacterial dissemination, granulomatous inflammation, caseation, tissue destruction.

Suggested GO terms: GO:0045730 (respiratory burst), GO:0042554 (superoxide anion generation), GO:0072593 (ROS metabolic process), GO:0042742 (defense response to bacterium), GO:0006909 (phagocytosis), GO:0043020 (NADPH oxidase complex — cellular component). Suggested CL terms: CL:0000235 (macrophage), CL:0000576 (monocyte), CL:0000775 (neutrophil), CL:0000451 (dendritic cell).

7. Anatomical Structures Affected

• Organ level (primary): lymph nodes (UBERON:0000029) — lymphadenitis; lungs (UBERON:0002048) — tuberculous pneumonitis; spleen (UBERON:0002106) and liver (UBERON:0002107) — organomegaly/granulomata; bone marrow (UBERON:0002371); skin (UBERON:0002097) with BCG-site/disseminated lesions.
• Body systems: immune/hematopoietic system (mononuclear phagocyte system); reticuloendothelial system; respiratory and lymphatic systems secondarily.
• Tissue/cell level: mononuclear phagocytes — tissue macrophages / monocyte-derived macrophages (CL:0000235) are the selectively affected population; monocytes, neutrophils, and dendritic cells are functionally spared.
• Subcellular level: phagosome/plasma membrane NADPH-oxidase complex (GO:0043020); electron transfer at the phagosomal membrane; ROS generation in the phagosomal lumen. Cellular components: GO:0005886 (plasma membrane), GO:0045335 (phagocytic vesicle).
• Localization / laterality: infection-site dependent; lymphadenopathy often regional then multifocal/bilateral; no fixed lateralization.

8. Temporal Development

• Onset: In the defining CYBB kindreds, adult-onset tuberculous disease in males; MSMD as a group is typically pediatric (mean ~10 yr) and frequently unmasked by infant BCG vaccination. Onset pattern is subacute–chronic, exposure-triggered.
• Progression: Disease course is episodic/infection-driven; individual episodes can be progressive and disseminated if untreated but are often controllable with therapy.
• Duration: Underlying genetic susceptibility is lifelong; infectious episodes require prolonged (months–years) antimycobacterial therapy.
• Remission: Treatment-induced remission with antimycobacterial regimens; relapse possible on re-exposure.
• Critical periods: peri-vaccination (BCG in infancy) and periods of M. tuberculosis exposure are windows of vulnerability; early diagnosis enables preventive intervention.

9. Inheritance and Population

• Inheritance pattern: X-linked recessive (hemizygous males affected; carrier females generally healthy). CYBB is one of only two X-linked MSMD genes (the other being IKBKG/NEMO) among the ~19–22 MSMD genes (25453225; 30264912; 42183200).
• Penetrance: Incomplete — a hallmark of MSMD; disease requires mycobacterial exposure. "Most of these inborn errors do not show complete clinical penetrance for the case-definition phenotype of MSMD" (25453225).
• Expressivity: Variable (from asymptomatic to disseminated disease).
• Sex ratio: Strongly male-predominant for CYBB-MSMD (X-linked recessive). MSMD overall ~52.5% male (38341181), but CYBB specifically affects males.
• Carrier females: generally protected via X-inactivation; carrier status transmissible. By analogy to X-linked CGD, a subgroup of female carriers with skewed lyonization (preferential inactivation of the wild-type X in myeloid cells) can become symptomatic; in XL-CGD such carriers may develop infection/inflammation and have been treated with allogeneic HSCT (37620741). An equivalent symptomatic-carrier scenario is theoretically possible for CYBB-MSMD if macrophage-lineage lyonization is unfavorable, though not yet formally reported.
• Anticipation / mosaicism / founder effects: No repeat-expansion anticipation; family-private alleles (no established founder effect for CYBB-MSMD).
• Consanguinity: Not required for X-linked CYBB-MSMD (relevant mainly to autosomal-recessive MSMD genes), but MSMD overall is enriched in consanguineous, high-TB-burden populations.
• Epidemiology: MSMD is a rare disease (no precise prevalence; estimates for individual etiologies are very low). Highest reported MSMD frequency in Iran, Turkey, Saudi Arabia (38341181). CYBB-MSMD is very rare — only a small number of kindreds reported worldwide.
• Geographic distribution: clusters in high-TB-burden and BCG-vaccinating regions; CYBB-MSMD kindreds reported in such settings.

10. Diagnostics

Functional / laboratory tests. - Respiratory burst assays — DHR (dihydrorhodamine-123) flow cytometry and NBT (nitroblue tetrazolium) test. Key diagnostic clue: in CYBB-MSMD these are normal in neutrophils/monocytes but defective in monocyte-derived macrophages — the opposite of the pan-phagocyte defect seen in X-CGD. This cell-type dissociation is pathognomonic and requires assaying differentiated macrophages, not just neutrophils. - gp91^phox protein expression / NADPH-oxidase component analysis by flow cytometry/immunoblot (LOINC-type functional assays). - Routine hematology/immunology are typically normal (part of the MSMD case definition). - Mycobacterial culture / tissue culture, mNGS/metagenomic sequencing, and histopathology of affected nodes (granulomatous inflammation ± acid-fast bacilli).

Genetic testing (definitive). - Single-gene CYBB sequencing or targeted MSMD/immunodeficiency NGS gene panels; WES/WGS used when panels are non-diagnostic (~50% of MSMD remains genetically unexplained, 42183200). - Distinguish MSMD-causing hypomorphic missense alleles from CGD-causing LoF alleles; functional segregation studies in macrophages confirm pathogenicity. - Maternal carrier testing / cascade testing for X-linked transmission.

Imaging. CT/MRI/ultrasound and PET for extent of lymphadenopathy, organomegaly, pulmonary and disseminated disease; chest imaging for TB.

Clinical criteria & differential diagnosis. - MSMD case definition: severe/recurrent disease from weakly virulent mycobacteria (BCG/NTM) — plus TB for CYBB — in otherwise healthy individuals. - Differential: X-linked CGD (broad bacterial/fungal susceptibility, pan-phagocyte DHR defect); other MSMD genes (IL12RB1, IL12B, IFNGR1/2, STAT1, IRF8, ISG15, TYK2, SPPL2A, NEMO); HIV/acquired immunodeficiency; anti-IFN-γ autoantibody syndrome.

Screening. Newborn screening does not currently capture MSMD/CYBB-MSMD (unlike SCID). In known kindreds: prenatal/carrier testing and avoidance of live BCG vaccine; cascade genetic screening of male relatives.

11. Outcome / Prognosis

• Survival/mortality: CYBB-MSMD, being narrowly mycobacterial and treatable, generally carries a better prognosis than CGD provided infections are recognized and treated. For the broader PID/BCG-disease population (MSMD 43%, CGD 26%): 5-year survival 80.3%, 10-year 69.3% (41748971).
• Morbidity: infection-related disability, prolonged therapy, occasional dissemination; between episodes patients are typically well.
• Disease course/complications: disseminated mycobacterial disease, granulomatous organ involvement, relapse on re-exposure; drug toxicity from prolonged antimycobacterials.
• Prognostic factors: early diagnosis and adequate antimycobacterial therapy; access to HSCT for refractory disease (HSCT markedly improves antimycobacterial success, 75.8% vs 0%, 41748971); virulence of infecting organism (M. tuberculosis worse than BCG/NTM).

12. Treatment

Pharmacotherapy (mainstay). - Prolonged combination antimycobacterial therapy tailored to organism (anti-tuberculous regimen for M. tuberculosis; anti-BCG/NTM regimens otherwise), often months to years. (NCIT: Antimycobacterial/Antitubercular Agent.) - Recombinant human IFN-γ (rhIFN-γ) — used adjunctively in MSMD (NCIT: Recombinant Interferon Gamma, C1512/Interferon Gamma C619). Caveat for CYBB-MSMD: because the lesion is a downstream effector defect (macrophage NADPH oxidase) with intact IFN-γ signaling, the rationale for IFN-γ is weaker than in cytokine-axis defects; response may be limited.

Curative / advanced therapeutics. - Allogeneic hematopoietic stem cell transplantation (HSCT) — "the sole curative yet high-risk option" for MSMD (42183200); replaces defective macrophage-lineage cells. (NCIT: Hematopoietic Cell Transplantation C15431.) - Gene therapy / gene editing — experimental; gene-corrected autologous HSC approaches (as explored for X-CGD) are conceptually applicable but not established for CYBB-MSMD. - Host-directed therapy (HDT) — experimental/conceptual: agents that boost macrophage antimycobacterial mechanisms are under study (e.g., phenothiazines restricting M. avium in primary human macrophages, partly NOX-ROS dependent, 40020517). Note: because such strategies leverage NOX-dependent ROS present in wild-type macrophages, they would not restore the absent burst in CYBB-null macrophages; HDT relevance to CYBB-MSMD is therefore theoretical and would need to target NOX-independent killing routes.

Surgical/supportive. Excision/drainage of suppurative lymph nodes as needed; supportive care; management of drug toxicity.

Treatment strategy. Genotype-guided: confirm CYBB-MSMD, treat the specific mycobacterium with prolonged combination therapy, consider adjunctive IFN-γ, and evaluate HSCT for severe/refractory/recurrent disease. Avoid further live BCG exposure.

13. Prevention

• Primary prevention: Avoid live BCG vaccination in at-risk families/known carriers (BCG is a major disseminated-disease trigger). Reduce M. tuberculosis exposure; TB infection-control measures in endemic regions.
• Secondary prevention: early recognition and treatment of mycobacterial disease; consider isoniazid/antimycobacterial prophylaxis after documented exposure per specialist guidance.
• Tertiary prevention: maintenance antimycobacterial therapy, surveillance for relapse, HSCT for refractory disease.
• Genetic prevention/counseling: genetic counseling for X-linked recessive inheritance; carrier testing of mothers/female relatives; prenatal/preimplantation testing options; cascade screening of male relatives.
• Public health: in high-TB-burden countries, weigh BCG timing/target populations against risk of severe adverse reactions in undiagnosed IEI (41668770 discusses BCG timing considerations).

14. Other Species / Natural Disease

• Taxonomy of pathogens (not host disease): M. tuberculosis (txid1773), M. bovis BCG (txid33892), M. avium (txid1764); host Homo sapiens (txid9606).
• Orthologous gene: mouse Cybb (NCBI Gene 13058), gp91^phox/Nox2 — highly conserved across mammals; the extracellular domain shows adaptive selection (23821607).
• Natural disease in animals: No well-described spontaneous macrophage-selective CYBB-MSMD equivalent in companion animals; CGD-like NADPH-oxidase deficiencies are documented in engineered models rather than natural populations. (OMIA has no established CYBB-MSMD entry.)
• Comparative biology: ROS-dependent macrophage control of mycobacteria is evolutionarily conserved; however, rodent macrophages rely more on nitric-oxide (iNOS) than ROS for mycobacterial killing, an important cross-species difference limiting model fidelity.
• Zoonotic potential: not applicable (host susceptibility trait, not transmissible).

15. Model Organisms

• Mouse (Mus musculus, txid10090):* Cybb/gp91^phox knockout mice are the established model of X-CGD (increased susceptibility to catalase-positive bacteria/fungi and to mycobacteria); MGI resources for Cybb alleles. These recapitulate pan-phagocyte oxidase loss (CGD), not* the macrophage-selective MSMD phenotype — a key limitation.
• Related NADPH-oxidase models: Duox1 KO mice show Duox1 is dispensable for the overall course of M. tuberculosis lung infection (36936954), underscoring that the microbicidal ROS relevant to mycobacteria derive chiefly from the NOX2/gp91^phox system.
• In vitro / cellular models (most faithful): patient monocyte-derived macrophages (MDMs) demonstrating the macrophage-selective respiratory-burst defect and failure to control intracellular M. tuberculosis (21278736; 27666509); EBV-B cell / fibroblast reconstitution and NADPH-oxidase assembly assays.
• Model limitations: No mouse reproduces the human cell-type-restricted (macrophage-only) NOX2 assembly defect; murine anti-mycobacterial immunity is more NO/iNOS-dependent, reducing translational fidelity for the ROS-centric human mechanism.
• Applications: dissecting macrophage-specific oxidase assembly, ROS-dependent mycobacterial killing, and testing of HSC gene-correction strategies.

Key References (PMID)

• 21278736 — Bustamante et al., Nat Immunol 2011. Landmark: germline CYBB mutations selectively affecting macrophages cause X-linked MSMD.
• 25453225 — Bustamante et al., 2014. MSMD genetic/immunologic/clinical review; CYBB and NEMO as X-linked MSMD genes.
• 30264912 — Rosain et al., 2019. MSMD 2014–2018 update.
• 42183200 — Qian et al., 2026. MSMD IFN-γ immunity review; 22 genes; treatment landscape (HSCT, gene editing).
• 41786143 — Johnston et al., 2026. MSMD management review.
• 38341181 — Khavandegar et al., 2024. Systematic review of 830 MSMD patients (epidemiology/phenotype).
• 41748971 — Xia et al., 2026. 15-yr BCG-disease cohort; survival and HSCT benefit.
• 27666509 — Khan et al., 2016. CYBB missense; MDMs fail to control intracellular M. tuberculosis.
• 23821607 — Tarazona-Santos et al., 2013. NADPH-oxidase gene structure/evolution.
• 31364312 — de Boer et al., 2019. CYBB/CYBA splicing mutations in CGD.
• 36936954 — Gupta et al., 2023. Duox1 dispensable in murine Mtb infection.
• 25703555 — Boisson-Dupuis et al., 2015. Inherited immunodeficiencies underlying childhood TB.
• 40020517 — Kilinç et al., 2025. NOX-derived ROS required for human-macrophage control of M. avium; host-directed therapy.
• 1531037 — Amezaga et al., 1992. IFN-γ transcriptionally regulates gp91phox/p47phox — links MSMD IFN-γ axis to the NOX2 effector.
• 37620741 — Tsilifis et al., 2023. HSCT for symptomatic female XL-CGD carriers; skewed lyonization.

Consolidated Evidence Synthesis (8 recorded findings)

Supported vs Refuted Hypotheses

• Supported: CYBB-MSMD is caused by macrophage-selective NADPH-oxidase (gp91^phox) assembly failure due to specific hypomorphic missense alleles; macrophage respiratory burst is essential for anti-mycobacterial immunity; disease is X-linked recessive with incomplete penetrance and mycobacteria-restricted phenotype.
• Refuted/excluded: CYBB-MSMD is NOT the same as X-linked CGD (different cell-type scope and clinical spectrum); it does NOT arise from an IL-12/IFN-γ signaling defect (that axis is intact); the phenotype is NOT a broad phagocyte immunodeficiency.

Limitations & Future Directions

• Very few kindreds worldwide → limited epidemiology, penetrance, and long-term outcome data specific to CYBB-MSMD.
• Precise variant-level annotation (exact HGVS/gnomAD frequencies) should be confirmed against ClinVar/HGMD for each reported allele.
• No faithful animal model of the macrophage-selective defect; mechanistic work relies on patient MDMs.
• Open questions: molecular basis of cell-type-restricted oxidase assembly; whether adjunctive IFN-γ benefits CYBB-MSMD; role of gene-corrected autologous HSCT.